Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1388-1395

  Kneifel, Stefan ^a   Bernhardt, Peter ^b   Uusijärvi, Helena ^b   Good, Stephan ^a   Plasswilm, Ludwig ^a   Buitrago Téllez, Carlos ^a   Müller Brand, Jan ^a   Mäcke, Helmut ^a   Merlo, Adrian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Dosimetry; Malignant glioma; NK 1 receptors; Substance P; Targeted radiotherapy

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; RADIOPHARMACEUTICAL AGENT; SUBSTANCE P IN 111; SUBSTANCE P Y 90; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRACHYTHERAPY; CAMERA; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOSIMETRY; FEMALE; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; MALE; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING;

ADULT; AGED; ANTIGENS, NEOPLASM; BRAIN; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; FEMALE; GLIOMA; HUMANS; LIGANDS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MODELS, THEORETICAL; RADIOMETRY; RADIOTHERAPY; REGRESSION ANALYSIS; SUBSTANCE P; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 34548182301     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0351-8     Document Type: Article

References (31)

1. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33.
2. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486-93.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
4. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61:786-92.
5. Eisenwiener KP, Powell P, Mäcke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000;10:2133-5.
6. Mäcke HR, Good S. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vértes A, Nagy S, Klencsár Z, editors. Handbook of nuclear chemistry. Amsterdam: Kluwer Academic; 2004. pp. 279-314.
7. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 2006;12:3843-50.
8. 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 1999;40:631-8.
9. 131I-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 2000;46:947-58.
10. 90Y-DOTATOC. J Nucl Med 2006;47:105-12.
11. Stewart RD, Wilson WE, McDonald JC, Strom DJ. Microdosimetric properties of ionizing electrons in water: a test of the PENELOPE code system. Phys Med Biol 2002;47:79-88.
12. Ye SJ, Brezovich IA, Pareek P, Naqvi SA. Benchmark of PENELOPE code for low-energy photon transport: dose comparisons with MCNP4 and EGS4. Phys Med Biol 2004;49:387-97.
13. Atherton E, Sheppard RC. Fluorenylmethoxycarbonylpolyamide solid phase peptide synthesis: general principles and development. In: Solid phase peptide synthesis: a practical approach. Eynsham, Oxford: IRL Press; 1989. pp. 25-37.
14. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974-81.
15. 99mTc ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 1989;30:599-604.
16. 99mTc-L,L-ECD for brain perfusion imaging, part 2: biodistribution and brain imaging in humans. J Nucl Med 1989;30:1902-10.
17. 99mTc ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J Nucl Med 1989;30:1018-24.
18. Shepp LA, Vardi Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans Med Imaging 1982;1:113-22.
19. Barnden LR, Hatton RL, Behin-Ain S, Hutton BF, Goble EA. Optimisation of brain SPET and portability of normal databases. Eur J Nucl Med Mol Imaging 2004;31:378-87.
20. Kim KM, Varrone A, Watabe H, Shidahara M, Fujita M, Innis RB, et al. Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities. J Nucl Med 2003;44:512-9.
21. Larsson A, Johansson L, Sundström T, Ahlström KR. A method for attenuation and scatter correction of brain SPECT based on computed tomography images. Nucl Med Commun 2003;24:411-20.
22. Shidahara M, Watabe H, Kim KM, Kato T, Kawatsu S, Kato R, et al. Development of a practical image-based scatter correction method for brain perfusion SPECT: comparison with the TEW method. Eur J Nucl Med Mol Imaging 2005;32:1193-8.
23. Vines DC, Ichise M, Liow JS, Toyama H, Innis RB. Evaluation of 2 scatter correction methods using a striatal phantom for quantitative brain SPECT. J Nucl Med Technol 2003;31:157-60.
24. Pietrzyk U, Herholz K, Heiss WD. Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr 1990;14:51-9.
25. Pietrzyk U, Herholz K, Schuster A, von Stockhausen HM, Lucht H, Heiss WD. Clinical applications of registration and fusion of multimodality brain images from PET, SPECT, CT, and MRI. Eur J Radiol 1996;21:174-82.
26. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22.
27. 125I: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-7.
28. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM (American Association of Physicists in Medicine) Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-34.
29. Prete JJ, Prestidge BR, Bice WS, Friedland JL, Stock RG, Grimm PD. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998;40:1001-5.
30. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
31. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42.